Documents
A list of downloadable documents created during development.
Background information
Psoriasis - infliximab: Final appraisal determination and comments on ACD
-
Consultee and commentator comments on the ACD
-
Commentators
-
Wyeth Pharmaceuticals 60.08 KB
-
Merck Serono 31.68 KB
-
Cochrane Skin Group 9.46 KB
-
Professional and patient groups
-
Royal College of Physicians 62.57 KB
-
The Psoriasis Association 25.23 KB
-
Schering Plough Ltd 423.47 KB
Psoriasis - infliximab: Appraisal Consultation Document
Psoriasis - infliximab: Evaluation report
-
Psoriasis - infliximab: Evaluation report
-
Pre-meeting briefing 174.75 KB
-
Psoriasis - infliximab: Non-manufacturer submissions
-
The Psoriasis Association 53.72 KB
-
Psoriatic Anthropathy Alliance 45.02 KB
-
British Dermatological Nursing Group 42.38 KB
-
Royal College of Physicians 44.31 KB
-
Psoriasis - infliximab: Manufacturer response to clarification letter
-
Manufacturer response A 239.39 KB
-
Manufacturer response B 735.23 KB
-
NICE clarification letter 26.65 KB
-
Psoriasis - infliximab: Expert written personal statements
-
Griffiths 20.42 KB
-
Barker 21.89 KB
-
Jackson 23.06 KB
-
Edwards 21.25 KB
-
Jobling 20.41 KB
Medicines concordance: Final scope
-
Medicines concordance: Final scope 39.27 KB
Medicines concordance: Final scope
-
Medicines concordance: Final scope 39.27 KB
Comments on draft scope and matrix and the Institute's response
Psoriasis - infliximab: Final scope archive
-
Medicines concordance: Final scope 39.27 KB